secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2024-04-03T23:59:59+00:00
Accession:  0001599298-24-000051
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit Therapeutics CFO resigns; COO Manmeet Soni appointed new CFO
-------------------------------------------------------------------

- CFO Ankur Dhingra resigned April 2, 2024, not due to any disagreement with the company.
- COO Manmeet Soni appointed CFO in addition to his COO role; receives $100K cash bonus and 1,100,000 options vesting over 4 years.
- Bhaskar Anand hired as Chief Accounting Officer, Head of Finance; salary $430K, 40% bonus, 1,200,000 options (half performance-based).
- New CFO Manmeet Soni previously CFO at Reata and Alnylam; both Soni and Anand are CPAs and Chartered Accountants.
- Anand previously served as CAO at Reata and assisted with a $7.5B merger with Biogen.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929824000051/0001599298-24-000051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929824000051/smmt-20240402.htm
  HTML page:      https://secwatch.observer/filing/0001599298-24-000051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer